{"generic":"Canakinumab","drugs":["Canakinumab","Ilaris"],"mono":{"0":{"id":"929409-s-0","title":"Generic Names","mono":"Canakinumab"},"1":{"id":"929409-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929409-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Cryopyrin associated periodic syndrome:<\/b> greater than 40 kg, 150 mg SUBQ every 8 weeks<\/li><li><b>Cryopyrin associated periodic syndrome:<\/b> 15 to 40 kg, 2 mg\/kg SUBQ every 8 weeks<\/li><li><b>Familial cold urticaria:<\/b> greater than 40 kg, 150 mg SUBQ every 8 weeks<\/li><li><b>Familial cold urticaria:<\/b> 15 to 40 kg, 2 mg\/kg SUBQ every 8 weeks<\/li><li><b>Gouty arthritis, acute:<\/b> 150 mg SUBQ as a single dose<\/li><li><b>Muckle-Wells syndrome:<\/b> greater than 40 kg, 150 mg SUBQ every 8 weeks<\/li><li><b>Muckle-Wells syndrome:<\/b> 15 to 40 kg, 2 mg\/kg SUBQ every 8 weeks<\/li><\/ul>"},"1":{"id":"929409-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in pediatric patients younger than 4 years with cryopyrin-associated periodic syndromes<\/li><li>safety and efficacy not established in pediatric patients younger than 2 years with systemic juvenile idiopathic arthritis<\/li><li><b>Cryopyrin associated periodic syndrome:<\/b> (4 years or older) greater than 40 kg, 150 mg SUBQ every 8 weeks<\/li><li><b>Cryopyrin associated periodic syndrome:<\/b> (4 years or older) 15 to 40 kg, 2 mg\/kg SUBQ every 8 weeks; may increase dose to 3 mg\/kg every 8 weeks in children with an inadequate response<\/li><li><b>Familial cold urticaria:<\/b> (4 years or older) greater than 40 kg, 150 mg SUBQ every 8 weeks<\/li><li><b>Familial cold urticaria:<\/b> (4 years or older) 15 to 40 kg, 2 mg\/kg SUBQ every 8 weeks; may increase dose to 3 mg\/kg every 8 weeks in children with an inadequate response<\/li><li><b>Muckle-Wells syndrome:<\/b> (4 years or older) greater than 40 kg, 150 mg SUBQ every 8 weeks<\/li><li><b>Muckle-Wells syndrome:<\/b> (4 years or older) 15 to 40 kg, 2 mg\/kg SUBQ every 8 weeks; may increase dose to 3 mg\/kg every 8 weeks in children with an inadequate response<\/li><li><b>Systemic onset juvenile chronic arthritis:<\/b> (2 years or older) body weight 7.5 kg or greater, 4 mg\/kg SUBQ every 4 weeks; MAX 300 mg\/dose<\/li><\/ul>"},"3":{"id":"929409-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cryopyrin associated periodic syndrome<\/li><li>Familial cold urticaria<\/li><li>Muckle-Wells syndrome<\/li><li>Systemic onset juvenile chronic arthritis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Gouty arthritis, acute<br\/>"}}},"3":{"id":"929409-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929409-s-3-9","title":"Contraindications","mono":"hypersensitivity, confirmed, to canakinumab or any component of the product <br\/>"},{"id":"929409-s-3-10","title":"Precautions","mono":"<ul><li>concomitant use with tissue necrosis factor inhibitors not recommended<\/li><li>concomitant use with live vaccines not recommended<\/li><li>hypersensitivity reactions have been reported; symptoms of underlying disease may mimic symptoms of hypersensitivity<\/li><li>infection, active and requiring medical intervention; use not recommended<\/li><li>infection, preexisting, history of recurring infection, or underlying conditions predisposing to infection; increased risk of developing serious infection<\/li><li>infections, including serious and opportunistic infections, have been reported; discontinue if serious infection develops<\/li><li>macrophage activation syndrome, potentially life-threatening, may occur; increased risk in patients with rheumatic conditions, including systemic juvenile rheumatoid arthritis<\/li><li>malignancy; risk of malignancy may increase with use<\/li><li>tuberculosis (TB), latent or active; increased risk for developing new TB infection or reactivation of latent infection; screen all patients for TB prior to initiation; treat latent TB before starting canakinumab therapy<\/li><li>report suspected adverse reactions to US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929409-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"929409-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929409-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (cryopyrin-associated periodic syndromes, 7% to 9%; systemic juvenile idiopathic arthritis, 10.7% to 12%)<\/li><li><b>Endocrine metabolic:<\/b>Weight increased (11%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (20%), Gastroenteritis (11%), Nausea (14%), Upper abdominal pain (systemic juvenile idiopathic arthritis, 7% to 16%)<\/li><li><b>Immunologic:<\/b>Infectious disease (systemic juvenile idiopathic arthritis, 30.2% to 54.8%)<\/li><li><b>Musculoskeletal:<\/b>Musculoskeletal pain (11%)<\/li><li><b>Neurologic:<\/b>Headache (14%), Vertigo (9% to 14%)<\/li><li><b>Respiratory:<\/b>Bronchitis (11%), Nasopharyngitis (34%), Pharyngitis (11%), Rhinitis (17%)<\/li><li><b>Other:<\/b>Influenza (17%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Macrophage activation syndrome<\/li><li><b>Respiratory:<\/b>Reactivation tuberculosis, Upper respiratory infection<\/li><\/ul>"},"6":{"id":"929409-s-6","title":"Drug Name Info","sub":{"0":{"id":"929409-s-6-17","title":"US Trade Names","mono":"Ilaris<br\/>"},"2":{"id":"929409-s-6-19","title":"Class","mono":"<ul><li>Immune Modulator<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"929409-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929409-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929409-s-7","title":"Mechanism Of Action","mono":"Canakinumab is a recombinant, human anti-human interleukin-1 beta (IL-1B) monoclonal antibody of the IgG1\/kappa isotype. By binding to human IL-1B, canakinumab blocks the IL-1 receptor interaction and neutralizes overactive IL-1B activity which is present in disorders such as Cryopyrin-Associated Periodic Syndromes (CAPS) and systemic juvenile idiopathic arthritis (SJIA). Canakinumab does not bind IL-1 alpha or IL-1 receptor antagonist (IL-ra).<br\/>"},"8":{"id":"929409-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929409-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, SubQ, adults: 7 days<\/li><li>Tmax, SubQ, pediatric patients: 2 to 7 days<\/li><li>Bioavailability, SubQ injection: 66%<\/li><\/ul>"},"1":{"id":"929409-s-8-24","title":"Distribution","mono":"Vd: 3.2 to 6.01 L <br\/>"},"3":{"id":"929409-s-8-26","title":"Excretion","mono":"0.11 to 0.174 L\/day <br\/>"},"4":{"id":"929409-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Adults, 26 days<\/li><li>Pediatric patients, 22.9 to 25.7 days<\/li><\/ul>"}}},"9":{"id":"929409-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>reconstitute each vial by slowly injecting 1 mL of preservative-free sterile water for injection; swirl vial slowly for approximately 1 minute and let stand for 5 minutes; reconstituted solution will have a concentration of 150 mg\/mL<\/li><li>gently turn vial upside down and back again 10 times; allow vial to stand at room temperature for 15 minutes to obtain a clear solution; do not shake; slight foaming of solution may occur<\/li><li>do not use if particulate matter is present; solution should be colorless or may have a slight brownish-yellow tint; do not use if solution has a distinctly brown color<\/li><li>if solution is not used within 60 minutes, it may be stored in the refrigerator at 2 to 8 degrees C and used within 4 hours<\/li><li>for subQ use only<\/li><li>do not inject into scar tissue, as this may cause insufficient exposure to drug<\/li><\/ul>"},"10":{"id":"929409-s-10","title":"Monitoring","mono":"<ul><li>cryopyrin-associated periodic syndromes: improvement in serum C reactive protein, serum amyloid A levels, and signs and symptoms of cryopyrin-associated periodic syndromes (eg, fever, urticaria-like rash, arthralgia, myalgia, fatigue, and conjunctivitis) may indicate efficacy<\/li><li>systemic juvenile idiopathic arthritis: improvement in serum C reactive protein and signs and symptoms of systemic juvenile idiopathic arthritis (eg, time between flare-ups and number of joints with active arthritis and limited range of motion) may indicate efficacy<\/li><li>tuberculosis screening; prior to initiation of therapy<\/li><li>macrophage activation syndrome (may be triggered by symptoms of worsening disease or infection); in patients with systemic juvenile idiopathic arthritis<\/li><\/ul>"},"11":{"id":"929409-s-11","title":"How Supplied","mono":"<b>Ilaris<\/b><br\/>Subcutaneous Powder for Solution: 180 MG<br\/>"},"13":{"id":"929409-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid live vaccines during therapy due to drug-induced immunosuppression.<\/li><li>Instruct patient to notify doctor immediately with symptoms of an infection or hypersensitivity.<\/li><li>Drug may cause immunosuppression, vertigo, diarrhea, influenza, nasopharyngitis, rhinitis, nausea, headache, and injection site reactions (eg, redness, itching, swelling, or warmth).<\/li><li>Advise patient to notify doctor if an injection site reaction is not healing or is getting worse.<\/li><\/ul>"}}}